ILMN Stock: Illumina, Inc. Stock Price, Analysis & Insights
Get live ilmn stock price $120.67, comprehensive Illumina, Inc. stock analysis, charts, news, and expert forecast. Real-time ilmn stock data and investment insights.
Loading chart...
Company Overview
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
Company Information
- CEO
- Jacob Thaysen
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 8970
Contact Information
- Website
- https://www.illumina.com
- Address
- 5200 Illumina Way
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Growth-oriented company with premium valuation (P/E: 27.1)
✓ Higher growth potential with elevated volatility (Beta: 1.45)
Business Model & Strategy
Illumina, Inc. operates in the Medical - Diagnostics & Research industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Jacob Thaysen, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Medical - Diagnostics & Research model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Illumina, Inc. competes in the Medical - Diagnostics & Research within the broader Healthcare. With 18.4 billion in market capitalization, the company is positioned as a established player in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Select, Illumina, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Illumina, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Illumina, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for mid-cap stocks
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Illumina, Inc.
- ⚠Investors should consider how Illumina, Inc. fits within their overall portfolio allocation
Market Cap
18.44B
P/E Ratio
27.06
Beta
1.45
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 18.44B market capitalization
- Trading Volume: 1.06M shares traded today
- Price Range: 52-week range of $68.70 - $153.06
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for Illumina, Inc.
Illumina, Inc. (ILMN) operates in the Medical - Diagnostics & Research industry within the Healthcare sector. With a current market capitalization of 18.44B, the company represents a significant player in its market. The stock is currently trading at $120.67 with a positivedaily change of 0.62%.
The company's 8970 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 27.06, beta of 1.45, and 52-week price range from $68.70 to $153.06when evaluating investment opportunities.
Why Invest in Illumina, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Jacob Thaysen
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.